Moderna's COVID-19 vaccine authorized (2020)
Moderna's mRNA COVID-19 vaccine won emergency use authorization about 11 months after the virus was sequenced, with roughly 94% efficacy in its pivotal trial. It made Moderna a major vaccine maker overnight.
The vaccine drove billions in sales and validated the mRNA platform at scale.
It set expectations Moderna is now trying to meet in harder diseases with weaker or shorter immunity.
COVID showed mRNA can move fast. Norovirus shows the platform still meets targets where immunity is short-lived and strains vary.
